glp-1 crohn's disease Weight Loss Medications & IBD A surprising role for enteroendocrine
Description
A genetic study supporting a relationship between glucagon-like peptide 1 receptor stimulation and the risk for non-medullary thyroid cancer
Once weight stabilises and the medication is discontinued, the additional GLP-1-driven risk diminishes
All patients were closely tracked for up to 5 years for any occurrence of the outcome of interests
Patients, and that's really what this is all about," Stevens said, adding that being the second small molecule drug will be important
What Is GLP-1 Related Fatigue
